|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
2007-2-28
|
|
pubmed:abstractText |
Tumors with multidrug resistance (MDR) frequently up-regulate efflux proteins, including MDR-associated protein (MRP-1) and P-glycoprotein (Pgp). MDR represents an obstacle to successful chemotherapy treatment and is reversible in Pgp- or MRP-1-expressing cells by the inhibitor VX-710. A Phase II study was designed to evaluate VX-710 in combination with doxorubicin and vincristine in patients with sensitive, recurrent small cell lung cancer (SCLC).
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
0008-543X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
109
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
924-32
|
|
pubmed:meshHeading |
pubmed-meshheading:17285598-Adult,
pubmed-meshheading:17285598-Aged,
pubmed-meshheading:17285598-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:17285598-Carcinoma, Small Cell,
pubmed-meshheading:17285598-Doxorubicin,
pubmed-meshheading:17285598-Drug Resistance, Multiple,
pubmed-meshheading:17285598-Female,
pubmed-meshheading:17285598-Humans,
pubmed-meshheading:17285598-Lung Neoplasms,
pubmed-meshheading:17285598-Male,
pubmed-meshheading:17285598-Middle Aged,
pubmed-meshheading:17285598-Neoplasm Recurrence, Local,
pubmed-meshheading:17285598-Piperidines,
pubmed-meshheading:17285598-Pyridines,
pubmed-meshheading:17285598-Vincristine
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
A phase II study of the safety and efficacy of the multidrug resistance inhibitor VX-710 combined with doxorubicin and vincristine in patients with recurrent small cell lung cancer.
|
|
pubmed:affiliation |
Massachusetts General Hospital, Boston, Massachusetts, USA.
|
|
pubmed:publicationType |
Journal Article,
Multicenter Study,
Clinical Trial, Phase II
|
